Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XBH111
- Development stage
- Preclinical
- Lead developer
- Shanghai XBH Biotechnology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
XBH111 is a preclinical-stage therapeutic candidate developed by GV20 Oncotherapy for the treatment of solid tumors. It utilizes a dual-modality platform, functioning as both an antibody-drug conjugate (ADC) and a T-cell engager. This design is intended to provide a multi-pronged attack on cancer cells by delivering a cytotoxic payload directly to the tumor while simultaneously redirecting and activating T cells to eliminate the malignant cells. The specific molecular targets for XBH111 have not been publicly disclosed.
Beyond the preview
Go deeper on XBH111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XBH111.